On April 15, 2026, the FDA announced the removal of BPC-157 from its 503A Category 2 list, effective April 22, 2026, because the original nominations were withdrawn
Without enough, you might face serious problems like megaloblastic anemia, tiredness, and nerve issues
Just pure self-indulgence
If youre a consumer or patient , BPC-157 is not an FDA-approved drug
DOSING & ADMINISTRATION Dosing is determined by your prescribing provider based on your specific situation
For those with recurring muscle tightness or lingering post-workout soreness, it could offer support within a comprehensive wellness protocol